The first in a provocative series on the complexities of advanced therapeutic approaches to cancer
By Jeff Brockman and Joel Sandler of Cello Health BioConsulting
“In 1890, the Russian playwright and physician Anton Chekov (pictured above) wrote a letter in which he alluded to a centuries-old observation that infections seemed to slow the growth of […]
11 March 2021
Cartherics is pleased to announce that on 8 March 2021 a review paper was approved for production and accepted for publication in the journal Frontiers in Genetics, section Cancer Genetics.
Titled: A role for integrin-linked kinase in colorectal cancer growth and progression via regulating senescence and immunity, the paper is a collaboration between Cartherics, […]
Melbourne, Australia, 04 March 2021.
Cartherics Pty Ltd announced today the grant of a European patent entitled “Genetically modified cells and uses thereof”. The patent covers aspects of Cartherics’ chimeric antigen receptor (CAR) technology, particularly in relation to its CAR directed against the tumour-associated antigen, TAG-72.
This patent is […]
By Leigh Dayton
4 March 2021
In 1966 Alan Trounson was enjoying a hike in the hills above Edinburgh, Scotland with his colleague Ian Wilmut when Wilmut revealed a secret. His team at the Roslin Institute had cloned a […]
Monash Grad Rachelle Duffin joins the team
1 March 2021
By Leigh Dayton
Fresh from a Research Assistant job at the Peter MacCallum Cancer Centre and a Bachelor of Science (Honours) from Monash University, Rachelle Duffin took up her new role at Cartherics at the beginning of February.
She’s “delighted and honoured” to be supervised by Cartherics […]
It all happened at Cape Schanck ……
By Leigh Dayton
24 February 2021
2020 was a rough year everywhere for everyone, including Cartherics’ hard-working team. By way of a thank you CEO Alan Trounson, Chairman Bob Moses and Chief Operating Officer Ian Nisbet hosted a company come-one come-all event this month at the Royal Automobile Club […]
A survey reveals nearly US$100 market capitalisation
23 February 2021
A survey conducted by Washington DC based BioInformant assesses the growth of the CAR-T arm of immunotherapy research and development. The summary is posted below.
At first the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus, and […]
By Leigh Dayton
4 February 2021
Not only is Alan Trounson Cartherics CEO and a leader in embryonic stem cell science, he’s also a pioneer in IVF technology. Back in 1980 the then embryologist made headlines for his participation in the birth of Australia’s first IVF baby, Candice Reed.
Thanks to this […]
By Leigh Dayton
21 December 2020
As a rough year for all comes to an end, Cartherics is delighted to raise a toast to Anisha Balachandran and Van Thi To. Anisha dressed-up for a pared-down graduation ceremony, and Van passed her Confirmation of Candidature Review with flying colours.
Cartherics CEO Alan Trounson is the […]
Writing today Research Australia’s INSPIRE magazine, Cartherics CEO Alan Trounson highlights the role GSK plays in supporting medical research
December 17 2020
By Leigh Dayton
For forty years the science-led global healthcare company has sponsored its GSK Award for Research Excellence. The Award acknowledges outstanding Australian researchers and provides an $80,000 (tax free) independent research grant to the […]
Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer, endometriosis and Alzheimer’s disease.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
